Cerecor to Present at Stifel Nicolaus Healthcare Conference

Stifel Nicolaus 2013 Global Healthcare Conference

BALTIMORE, Md.--()--Cerecor Inc., a biopharmaceutical company developing neuroscience drugs that make a difference in underserved patient segments of common diseases, today announced that Blake Paterson, MD, CEO and Co-Founder, will present an overview of the Company’s strategy and pipeline candidates at the 2013 Stifel Nicolaus Healthcare Conference in Boston. The presentation will take place on Wednesday, September 11, 2013, at 10:20am Eastern Time.

About Cerecor

Cerecor Inc. is a privately held biopharmaceutical company focused on the development and commercialization of prescription pharmaceuticals whose primary site of activity is in the human nervous system. The Company is developing first-in-class drugs where human proof-of-concept has been established for the target, the molecule, or both in conditions for which established biomarkers are available to facilitate development. Cerecor’s programs address the needs of underserved sub-segments of major diseases. Cerecor increases the probability of clinical success by employing specific trial methodologies that reduce placebo response rates and enhance efficacy signals. www.cerecor.com

Contacts

MacDougall Biomedical Communications
Michelle Avery, 781-235-3060
mavery@macbiocom.com
or
Christine Labaree, 650-339-7533
clabaree@macbiocom.com

Release Summary

Cerecor's CEO and Co-Founder Blake Paterson, MD, will present an overview of the company strategy and pipeline candidates at the 2013 Stifel Nicolaus Healthcare Conference in Boston.

Contacts

MacDougall Biomedical Communications
Michelle Avery, 781-235-3060
mavery@macbiocom.com
or
Christine Labaree, 650-339-7533
clabaree@macbiocom.com